- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-5076
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Chimeric antigen receptor T‑cell therapy—a hematological success story ; volume:11 ; number:2 ; day:6 ; month:6 ; year:2018 ; pages:116-121 ; date:6.2018
Magazine of European Medical Oncology ; 11, Heft 2 (6.6.2018), 116-121, 6.2018
- Urheber
-
Wohlfarth, Philipp
- Beteiligte Personen und Organisationen
-
Worel, Nina
Hopfinger, Georg
SpringerLink (Online service)
- DOI
-
10.1007/s12254-018-0409-x
- URN
-
urn:nbn:de:101:1-2018082823473270980603
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wohlfarth, Philipp
- Worel, Nina
- Hopfinger, Georg
- SpringerLink (Online service)
Ähnliche Objekte (12)
Chimeric Antigen Receptor T-Cell Therapy
Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future
Cellular Immunotherapy for Hematological Disorders : From Allogeneic Stem Cell Transplantation to Chimeric Antigen Receptor-engineered T-cell Application
A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies
Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
Improvement of chimeric antigen receptor T cell therapy for patients with hematological malignancies
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice
Chimeric Antigen Receptor T-Cell Therapy
Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future
Cellular Immunotherapy for Hematological Disorders : From Allogeneic Stem Cell Transplantation to Chimeric Antigen Receptor-engineered T-cell Application
A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies
Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
Improvement of chimeric antigen receptor T cell therapy for patients with hematological malignancies
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice
Chimeric Antigen Receptor T-Cell Therapy
Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future
Cellular Immunotherapy for Hematological Disorders : From Allogeneic Stem Cell Transplantation to Chimeric Antigen Receptor-engineered T-cell Application
A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies
Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
Improvement of chimeric antigen receptor T cell therapy for patients with hematological malignancies
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies